[2]
Amandeep Thakur, Arshdeep Singh, Navdeep kaur, Ritu Ojha, Kunal Nepali*. Steering the antitumor drug discovery campaign towards structurally diverse indolines. Bioorg. Chem., 2020, 94, 103436.
[3]
Kunal Nepali, Hsueh-Yun Lee, Jing-Ping Liou. Nitro group containing drugs. J. Chem., 2019, 62, 2851-2893.
[4]
Kunal Nepali, Mei-Hsiang Lin, Min-Wu Chao, Sheng-Jhih Peng, Kai-Cheng Hsub, Tony Eight Lin, Mei-Chuan Chen, Mei-Jung Lai, Shiow-Lin Pan, Jing-Ping Liou. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorg. Chem., 2019, 91, 103119.
[5]
Hsueh-Yun Lee#, Kunal Nepali#, Fang-I Huang#, Chih-Yi Chang, Mei-Jung Lai, Yu-Hsuan Li, Hsiang-Ling Huang, Chia-Ron Yang, Jing-Ping Liou. (N-Hydroxycarbonylbenylamino) quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in vitro and in vivo. J. Med. Chem., 2018, 61, 905-917.
[6]
Kunal Nepali, Hsueh-Yun Lee, Mei-Jung Lai, Ritu Ojha, Tung-Yun Wu, Gu-Xian Wu, Mei-Chuan Chen, Jing-Ping Liou. Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. Eur. J. Med. Chem., 2017, 127, 115-127.
[7]
Manroopraj Kaur, Amandeep Kaur, Suhani Mankotia, Harbinder Singh, Arshdeep Singh, Jatinder Vir Singh, Manish Kumar Gupta, Sahil Sharma, Kunal Nepali*, Preet Mohinder Singh Bedi. Synthesis, screening and docking of fused pyrano [3, 2-d] pyrimidine derivatives as xanthine oxidase inhibitor. Eur. J. Med. Chem., 2017, 131, 14-28.
[8]
Harbinder Singh, Jatinder Vir Singh, Manish K Gupta, Palwinder Singh, Sahil Sharma, Kunal Nepali*, Preet Mohinder S Bedi. Benzoflavones as cholesterol esterase inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2017, 27, 850-854.
[9]
Harbinder Singh, Jatinder Vir Singh, Manish K Gupta, Ajit K Saxena, Sahil Sharma, Kunal Nepali*, Preet Mohinder S Bedi*. Triazole tethered isatincoumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Bioorg. Med. Chem. Lett., 2017, 27, 3974-3979.
[10]
Kunal Nepali, Ritu Ojha, Hsueh-Yun Lee, Jing-Ping Liou. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opin. Investig. Drugs, 2016, 25, 917-936.
[11]
Kunal Nepali, Sunil Kumar, Hsiang-Ling Huang, Fei-Chiao Kuo, Cheng-Hsin Lee,Ching-Chuan Kuo , Teng-Kuang Yeh, Yu-Hsuan Li, Jang-Yang Chang, Jing-Ping Liou and Hsueh-Yun Lee. 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Org. Biomol. Chem., 2016, 14, 716-723.
[12]
Ritu Ojha, Jagjeet Singh, Anu Ojha, Harbinder Singh, Sahil Sharma, Kunal Nepali*. An updated patent review: Xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)" Expert Opin. Ther. Pat., 2016, 27, 311-345.
[13]
Sahil Sharma, Jagjeet Singh, Ritu Ojha, Harbinder Singh, Manpreet Kaur, P.M.S. Bedi, Kunal Nepali*. Design Strategies, Structure Activity Relationship and Mechanistic Insights for Purines as Kinase Inhibitors. Eur. J. Med. Chem., 2016, 112, 298-346.
[14]
Samir Mehndiratta, Sameer Sapra, Manwinder Singh, Kunal Nepali*. Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature. Recent Patents Anticancer Drug Discov., 2016, 11, 2-66.
[15]
Arshdeep Singh, Navdeep Kaur, Gurpreet Singh, Sahil Sharma, Pooja Sharma, Kunal Nepali*. Topoisomerase I and II Inhibitors: A Patent Review. Rec. Pat. Anti-Cancer Drug Discov., 2016, 11, 401-423.
